Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-25995
Mol Cell Biochem 1990 Mar 27;932:141-6.
Show Gene links Show Anatomy links

Inhibition of transcription by adriamycin is a consequence of the loss of negative superhelicity in DNA mediated by topoisomerase II.

Tarr M , van Helden PD .


???displayArticle.abstract???
Adriamycin is commonly used as a chemotherapeutic agent and is known to intercalate into the major groove of DNA and inhibit DNA and RNA synthesis. Results presented in this communication suggest that adriamycin affects topoisomerase cleavage of DNA. The resultant change in negative superhelicity (decrease) is responsible for the decrease in transcription. This process is not dependent on the continued presence of adriamycin. The reaction between topoisomerases, DNA and adriamycin is dose-dependent. The results help to explain the relatively enhanced cytotoxicity of this drug to tumor cells.

???displayArticle.pubmedLink??? 2161074




References [+] :
Bertrand-Burggraf, Effect of superhelicity on the transcription from the tet promoter of pBR322. Abortive initiation and unwinding experiments. 1984, Pubmed